Skip to main content
VALIRX PLC logo

VALIRX PLC — Investor Relations & Filings

Ticker · VAL ISIN · GB00BLH13C52 LEI · 213800VQKB9SJCQDET40 IL Professional, scientific and technical activities
Open in API
Filings indexed 574 across all filing types
Latest filing 2021-08-20 Regulatory Filings
Country GB United Kingdom
Listing IL VAL

About VALIRX PLC

https://www.valirx.com/

ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1909 characters) and contains the header 'RNS Number : 3583J' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Price Monitoring Extension' for a security, which is a specific, brief operational announcement related to trading mechanics, not a comprehensive financial report or a formal filing like a 10-K or ER. Since it is a general regulatory announcement disseminated via the RNS system that doesn't fit into the more specific categories (like DIV, DIRS, or ER), it falls best under the general Regulatory Filings category, which serves as a fallback for miscellaneous regulatory news.
2021-08-20 English
Patent update
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated '06 July 2021'. It reports on 'Patent Status Update' and provides specific details about patent grants for various projects (VAL201, VAL301, VAL401) during the first half of 2021. The closing section explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a regulatory news service announcement. Since the content is a specific update on intellectual property progress rather than a general financial report (like 10-K or IR) or a management change (MANG), it fits best under the general regulatory announcement category, RNS, as it is a mandatory disclosure via the LSE's primary information provider.
2021-07-06 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1924 characters) and announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange, identified by the 'RNS Number'. It explicitly states that the information is provided by RNS, the news service of the London Stock Exchange, and is approved by the Financial Conduct Authority (FCA) as a Primary Information Provider. This type of immediate, regulatory-driven announcement that doesn't fit a specific financial reporting category (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing or Announcement, which corresponds to the RNS code.
2021-06-17 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1907 characters) and its primary content is an announcement regarding a 'Price Monitoring Extension' for a security on the London Stock Exchange, referencing the RNS system and the Financial Conduct Authority (FCA). It does not contain detailed financial statements, management discussion, or specific voting results. It is a brief, operational regulatory update disseminated via the RNS news service. Since it is a general regulatory announcement that doesn't fit the specific categories like DIV, DIRS, or ER, the most appropriate classification is the general Regulatory Filings category (RNS).
2021-06-17 English
Result of AGM
AGM Information Classification · 1% confidence The document explicitly states its purpose in the title and body: "Result of AGM" and "ValiRx plc announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed." This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. Although it reports the result, the context is the AGM event itself. It is not a DEF 14A (Proxy) or DVA (Voting Results), but rather a general announcement related to the meeting's conclusion.
2021-05-27 English
KTH222 Evaluation Agreement Concluded
M&A Activity Classification · 1% confidence The document is a formal announcement disseminated via RNS (RNS Number : 9600Z) from ValiRx PLC on May 27, 2021. The content details the conclusion of an evaluation agreement regarding a drug candidate (KTH222) and the decision to terminate the agreement. This is a specific corporate action update concerning a business development/licensing decision, not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it is a formal, non-standard announcement released through the RNS system, and it doesn't fit perfectly into categories like M&A (TAR) or Capital Change (CAP), the most appropriate general regulatory filing category for miscellaneous corporate news released via RNS is the fallback category, Regulatory Filings (RNS). The document length is short (4388 chars), suggesting it is an announcement rather than the full underlying report.
2021-05-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.